Literature DB >> 7462698

The critical role of complement in experimental pneumococcal sepsis.

S W Hosea, E J Brown, M M Frank.   

Abstract

Using a guinea pig model fo bacteremia due to Streptococcus pneumoniae serotype 7, opsonization by the classical and alternative pathways of complement activation was studied in immune and nonimmune animals. Depletion of the alternative complement pathway and complement components C3-C9 resulted in a significant, lethal defect of intravascular clearance in both normal and immune animals. Preopsonization corrected the initial clearance defect in complement-depleted animals. Maximal rates of clearance of bacteremia occurred in immune, normal animals, Immune, C4-deficient animals had clearance curves similar to normal, nonimmune animals. Thus, optimal clearance of pneumococcal bacteremia requires an intact alternative an classical pathway of complement activation. In the nonimmune animal, the alternative pathway provides the primary host defense against infection, whereas after immunization, optimal clearance of bacteremia requires an intact classical pathway of complement activation. However, immunization does not alter the lethal clearance defect in complement-depleted animals.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7462698     DOI: 10.1093/infdis/142.6.903

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia.

Authors:  R B Alcantara; L C Preheim; M J Gentry-Nielsen
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

4.  The effects of PspC on complement-mediated immunity to Streptococcus pneumoniae vary with strain background and capsular serotype.

Authors:  Jose Yuste; Suneeta Khandavilli; Naadir Ansari; Kairya Muttardi; Laura Ismail; C Hyams; Jeffrey Weiser; Timothy Mitchell; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

5.  The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.

Authors:  Jeremy S Brown; Tracy Hussell; Sarah M Gilliland; David W Holden; James C Paton; Michael R Ehrenstein; Mark J Walport; Marina Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

6.  Effect of complement depletion on anticapsular-antibody-mediated immunity to experimental infection with Haemophilus influenzae type b.

Authors:  J R Schreiber; C J Basker; G R Siber
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

7.  Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia.

Authors:  M A Mellencamp; L C Preheim; T L McDonald
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

8.  Role of complement in mouse macrophage binding of Haemophilus influenzae type b.

Authors:  G J Noel; D M Mosser; P J Edelson
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

9.  Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.

Authors:  W M Scheld; M A Sande
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

10.  Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules.

Authors:  E J Brown; M Berger; K A Joiner; M M Frank
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.